엘앤씨바이오, ‘메가카티’로 아시아 8개국 퇴행성관절염 치료 시장 본격 진출 > 보도자료

CATALOG

CONTACT

ENG

CHN

KOR

CATALOG

CONTACT

엘앤씨바이오, ‘메가카티’로 아시아 8개국 퇴행성관절염 치료 시장 본격 진출

Writer admin

Date 25-10-17 16:43

Views 54

본문

의학신문

엘앤씨바이오, ‘메가카티’로 아시아 8개국 퇴행성관절염 치료 시장 본격 진출

디지틀조선일보

엘앤씨바이오, ‘메가카티’로 아시아 8개국 진출…퇴행성관절염 치료 시장 공략

L&C Bio Co., Ltd. Business Registration No. (129-86-64008) Privacy Policy Seoul Office / R&D Center 82, Naruteo-ro, Seocho-gu, Seoul (Jamwon-dong) Seoul Office / Sales & Marketing Center Room 201, 105, HyoRyeong-ro (Beomchang Bldg., Bangbae-dong), Seocho-gu, Seoul Headquarters / Human Tissue Plant Units 605–607, 474, Dunchon-daero, Suntech City (Sangdaewon-dong), Jungwon-gu, Seongnam-si, Gyeonggi-do Pharmaceutical Plant Building A, 1F, 104, Gongdan 2-ro, (Sinsohyeon-dong), Anseong-si, Gyeonggi-do L&C ES Headquarters 2F #203–204, 90, Centum-dong-ro, L&C ES (Jaesong-dong, Centum Phil Bldg. 2), Haeundae-gu, Busan L&C ES R&D Center 4F, 76, Naruteo-ro (ImageUp Bldg.), Seocho-gu, Seoul L&C Medicare Headquarters Room 202, 105, HyoRyeong-ro (Beomchang Bldg., Bangbae-dong), Seocho-gu, Seoul L&C China Headquarters No. 97, Building 32-1, Jixiangnan Yuan, Luojia Town, Kunshan, Jiangsu, China

Cutomer Service

+82-2-541-8577